C12orf49 Inhibitors
Chemical inhibitors of C12orf49 function through a variety of mechanisms to disrupt its activity within cellular signaling pathways. Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, play a pivotal role in this process. By inhibiting PI3K, these chemicals prevent the phosphorylation and activation of AKT, a kinase that is often associated with the same signaling cascades as C12orf49. This results in a blockade of the downstream signaling events that are essential for the function of C12orf49. Similarly, LY294002's specific inhibition of AKT activation leads to a decrease in the phosphorylation of proteins that are necessary for C12orf49's activity. Staurosporine, a broad-spectrum kinase inhibitor, further extends this inhibition by targeting a wide range of kinases that are responsible for phosphorylating C12orf49, thereby preventing its functional activity.
Additional inhibitors, such as Rapamycin, SB203580, U0126, PD98059, SP600125, PP2, Dasatinib, Sorafenib, and Sunitinib, each target different aspects of the signaling pathways involving C12orf49. Rapamycin specifically inhibits the mechanistic target of rapamycin (mTOR), which is central to cellular growth and proliferation pathways that may regulate C12orf49's function. SB203580 and U0126 focus on the MAPK pathways, with the former inhibiting p38 MAPK and the latter targeting MEK1/2, both of which could influence C12orf49 activity. PD98059 also inhibits MEK, which prevents the activation of ERK, a kinase that could activate C12orf49. SP600125 adds another layer of inhibition by targeting JNK, which is potentially involved in C12orf49's signaling pathways. Src family kinases, which are implicated in various signaling processes, are inhibited by PP2, while Dasatinib extends this inhibition to Bcr-Abl and Src family kinases. Finally, the receptor tyrosine kinase inhibitors Sorafenib and Sunitinib disrupt multiple kinases, leading to a broad inhibition of signaling pathways that C12orf49 uses for its functional activity. Each of these inhibitors contributes to the collective inhibition of C12orf49 by targeting different molecules that regulate its function within cells.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are involved in signaling pathways that the protein C12orf49 may be part of. Through inhibition of PI3K, downstream signaling that contributes to the function of C12orf49 is hindered, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents the activation of AKT, a kinase that could be implicated in the same pathway as C12orf49. Inhibition of this pathway leads to reduced phosphorylation and activation of proteins, including C12orf49, thus inhibiting its function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit kinases that are responsible for the phosphorylation of C12orf49, which is necessary for its function. This inhibition of kinase activity results in the functional inhibition of C12orf49. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin) which is a central protein in a signaling pathway that regulates cell growth and proliferation, possibly involving C12orf49. Inhibition of mTOR leads to a decrease in the functional activity of C12orf49. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAPK. If C12orf49 function is regulated via the p38 MAPK pathway, this inhibitor would disrupt its signaling and thereby inhibit the functional activity of C12orf49. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream in the MAPK/ERK pathway, a pathway possibly utilized by C12orf49. Inhibition of MEK1/2 by U0126 would therefore inhibit the function of C12orf49 by blocking this necessary signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which would prevent the activation of ERK. Since ERK may be involved in the activation of C12orf49, PD98059 would inhibit its function by blocking the pathway at this point. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which could be involved in the signaling pathways of C12orf49. Inhibition of JNK would lead to the functional inhibition of C12orf49 by preventing the activation of its signaling pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases that are implicated in various signaling pathways, possibly including those of C12orf49. Inhibition of Src kinases by PP2 would lead to the functional inhibition of C12orf49. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Bcr-Abl and Src family kinases. As these kinases are involved in numerous signaling pathways, their inhibition by Dasatinib could lead to the functional inhibition of C12orf49. | ||||||